甲胺和SGLT2i作为2型糖尿病的第一线组合疗法:以种族为重点的现实研究
Matthew Anson1, Sizheng Steven Zhao2, Hani Essa3
1Diabetes & Endocrinology Research and Pain Research Institute, Institute of Life Course and Medical Sciences, University of Liverpool and Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom.
Clinical therapeutics
|August 30, 2023
概括
2型糖尿病 (T2D) 的早期组合治疗改善了心脏结结果. 这种密集的治疗对黑人和亚洲人来说比白人更有好处,突出了T2D管理中种族的重要性.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在2型糖尿病 (T2D) 中,低于最佳的葡萄糖控制导致显著的长期发病率和死亡率,这种现象被称为"血糖遗传".
- 与白人相比,黑人和亚洲族裔的个人患T2D及其并发症的风险更高.
- 目前的T2D治疗算法不考虑种族,与其他心血管疾病管理不同.
研究的目的:
- 评估早期密集组合治疗与标准治疗对T2D患者心脏和脏结局的现实影响.
- 具体评估种族对治疗有效性的影响.
主要方法:
- 使用TriNetX平台进行了回顾性队列研究,分析了匿名的医疗记录.
- 被诊断为T2D的患者被分为两组:在诊断后一个月内接受甲胺和SGLT2抑制剂 (SGLT2i) 的患者,以及仅接受甲胺的患者.
- 心血管和的结果在三年后被评估,分析按种族分层.
主要成果:
- 与仅服用甲胺的组相比,接受甲胺和SGLT2i的组显示死亡,慢性病 (CKD),糖尿病病,心力衰竭和住院的风险明显较低.
- 与白人相比,黑人个体的死亡率和缺血性心脏病 (IHD) 风险降低.
- 与白人相比,亚洲人的心力衰竭和住院风险较低.
结论:
- 在T2D诊断的第一年内开始使用Metformin和SGLT2i的组合疗法会导致比标准疗法更好的心脏结局.
- 早期密集治疗的好处在黑人和亚洲人群中显得更加明显.
- 需要进一步的前性研究,重点关注T2D治疗中的种族差异.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Oral Hypoglycemic Agents: Glinides
184
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
184
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Oral Hypoglycemic Agents: Sulfonylureas
236
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
236
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
205
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
205


